Literature DB >> 26427117

Effect of Liuweidihuang pill and Jinkuishenqi pill on inhibition of spontaneous breast carcinoma growth in mice.

Lixiang Zheng, Hongning Liu, Yan Gong, Xianming Meng, Runde Jiang, Xiaomin Wang, Qiaofeng Wang, Yue Wang.   

Abstract

OBJECTIVE: To investigate the preventing and treating action of Liuweidihuang pill (LP) and Jinkuishenqi pill (JP) on spontaneous breast carcinoma in mice.
METHODS: A model of spontaneous breast carcinoma was derived from 11.5-month-old female Kunming breeding mice following the delivery of several litters. The mice were randomly divided into five groups: model control group (C), Liuweidihuang pill high-dose group (LH; 4.6 g · kg(-1) · d(-1)), Liuweidihuang pill low-dose group (LL; 2.3 g · kg(-1) · d(-1)), Jinkuishenqi pill high-dose group (JH; 4.6 g · kg(-1) · d(-1)) and Jinkuishenqi pill low-dose group (JL; 2.3 g · kg(-1) · d(-1)). Cancer tissue volume was measured by water immersion. Histopathology was analyzed by hematoxylin and eosin staining. Vascular endothelial growth factor (VEGF), extracellular signal-regulated kinase (ERK) and cyclin D1 protein expression in cancer tissue was assayed by western blotting.
RESULTS: Compared with the control group, cancer tissue volume and weight were lower in the LP and JP groups, and survival time was longer. The expression of VEGF, ERK and Cyclin D1 were inhibited in the LP and JP groups (P < 0.05), and cell differentiation was increased. Tumor weights and volumes and VEGF, ERK and Cyclin D1 expression in LL or LH were significantly lower than in JL and JH (P < 0.01).
CONCLUSION: Both LP and JP could restrain cancer growth and promote cancer cell differentiation; moreover, LP was more effective than JP The likely mechanism of action was via inhibition of VEGF, ERK and cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26427117     DOI: 10.1016/s0254-6272(15)30124-2

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  2 in total

Review 1.  Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach.

Authors:  Laleh Arzi; Homa Mollaei; Reyhane Hoshyar
Journal:  Plants (Basel)       Date:  2022-08-24

2.  Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study.

Authors:  Yin-Ying Wang; Hong Bai; Run-Zhi Zhang; Hong Yan; Kang Ning; Xing-Ming Zhao
Journal:  Oncotarget       Date:  2017-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.